Lista de obras -

A critical analysis and review of Lancet COVID-19 hydroxychloroquine study

artículo científico publicado en 2020

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting

artículo científico publicado en 2017

Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram

artículo científico publicado en 2015

Characteristics of doctor-shoppers: a systematic literature review

article

Cultural differences in stigma surrounding schizophrenia: comparison between Central Europe and North Africa

artículo científico publicado en 2015

Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement.

artículo científico publicado en 2016

Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom - findings from the European Schizophrenia Cohort (EuroSC).

scientific article published on 28 March 2009

Economic burden for Alzheimer's disease in China from 2010 to 2050: a modelling study

scientific article published on 26 September 2019

Factors contributing to frequent use of psychiatric inpatient services by schizophrenia patients

artículo científico publicado en 2004

Health economic evaluation of gene replacement therapies: methodological issues and recommendations

artículo científico publicado en 2020

Health related quality of life in patients having schizophrenia negative symptoms - a systematic review

article

Health-related quality of life of patients after ischaemic stroke treated in a provincial hospital in Poland

artículo científico publicado en 2020

Healthcare resource use in schizophrenia, EuroSC findings

artículo científico publicado en 2017

Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders

artículo científico publicado en 2014

Non-profit drug research and development: the case study of Genethon

article

Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France

scientific article published on 15 February 2019

Patient-reported outcome claims in European and United States orphan drug approvals

artículo científico publicado en 2018

Positive and negative symptoms in schizophrenia: A longitudinal analysis using latent variable structural equation modelling

artículo científico publicado en 2018

President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients First

scientific article published on 04 March 2019

Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe

artículo científico publicado en 2016

Quantifying the persisting orphan-drug shortage public health crisis in the United States

artículo científico

Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.

artículo científico publicado en 2017

The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate

artículo científico publicado en 2016

The mediating role of depression in pathways linking positive and negative symptoms in schizophrenia. A longitudinal analysis using latent variable structural equation modelling

artículo científico publicado en 2019

The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change

artículo científico publicado en 2017

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines.

artículo científico

Why "American Patients First" is likely to raise drug prices outside of the United States

artículo científico publicado en 2019

Lista de obras de

A critical analysis and review of Lancet COVID-19 hydroxychloroquine study

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting

Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram

Characteristics of doctor-shoppers: a systematic literature review

Cultural differences in stigma surrounding schizophrenia: comparison between Central Europe and North Africa

Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement.

Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom - findings from the European Schizophrenia Cohort (EuroSC).

Economic burden for Alzheimer's disease in China from 2010 to 2050: a modelling study

Factors contributing to frequent use of psychiatric inpatient services by schizophrenia patients

Health economic evaluation of gene replacement therapies: methodological issues and recommendations

Health related quality of life in patients having schizophrenia negative symptoms - a systematic review

Health-related quality of life of patients after ischaemic stroke treated in a provincial hospital in Poland

Healthcare resource use in schizophrenia, EuroSC findings

Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders

Non-profit drug research and development: the case study of Genethon

Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France

Patient-reported outcome claims in European and United States orphan drug approvals

Positive and negative symptoms in schizophrenia: A longitudinal analysis using latent variable structural equation modelling

President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients First

Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe

Quantifying the persisting orphan-drug shortage public health crisis in the United States

Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.

The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate

The mediating role of depression in pathways linking positive and negative symptoms in schizophrenia. A longitudinal analysis using latent variable structural equation modelling

The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines.

Why "American Patients First" is likely to raise drug prices outside of the United States